Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Update

20 Jan 2026, 17:40 by Scott Moore · The Cerbat Gem

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 8,454,052 shares, an increase of 20.7% from the December 15th total of 7,001,428 shares. Approximately 13.9% of the company’s stock are sold short. Based on an average trading volume of 1,459,903 shares, the days-to-cover ratio is presently 5.8 days. Based on an average trading volume of 1,459,903 shares, the days-to-cover ratio is presently 5.8 days. Approximately 13.9% of the company’s stock are sold short.

Insider Buying and Selling at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total value of $128,396.34. Following the completion of the transaction, the chief executive officer directly owned 618,937 shares of the company’s stock, valued at $14,538,830.13. This represents a 0.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 6.50% of the company’s stock.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of GLUE. Nisa Investment Advisors LLC boosted its holdings in shares of Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares during the period. Royce & Associates LP raised its position in shares of Monte Rosa Therapeutics by 8.3% in the third quarter. Royce & Associates LP now owns 11,024 shares of the company’s stock valued at $82,000 after purchasing an additional 848 shares during the period. GAMMA Investing LLC bought a new stake in shares of Monte Rosa Therapeutics during the 4th quarter worth $30,000. Allspring Global Investments Holdings LLC grew its stake in Monte Rosa Therapeutics by 9.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 26,955 shares of the company’s stock valued at $423,000 after buying an additional 2,358 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Monte Rosa Therapeutics by 2.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 119,836 shares of the company’s stock worth $540,000 after acquiring an additional 2,529 shares during the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on GLUE shares. Wells Fargo & Company upped their price objective on Monte Rosa Therapeutics from $22.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, January 8th. Guggenheim boosted their target price on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Wedbush reissued an “outperform” rating and set a $37.00 target price on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Finally, Cowen reaffirmed a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.33.

View Our Latest Research Report on Monte Rosa Therapeutics

Monte Rosa Therapeutics Stock Up 3.1%

Monte Rosa Therapeutics stock traded up $0.73 during midday trading on Tuesday, hitting $24.44. The company’s stock had a trading volume of 1,282,988 shares, compared to its average volume of 3,696,296. Monte Rosa Therapeutics has a 12 month low of $3.50 and a 12 month high of $25.77. The company has a market capitalization of $1.59 billion, a PE ratio of 76.38 and a beta of 1.60. The stock’s 50-day moving average price is $17.36 and its 200-day moving average price is $10.62.

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.06. The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $7.37 million. Monte Rosa Therapeutics had a net margin of 11.54% and a return on equity of 8.28%. As a group, equities analysts anticipate that Monte Rosa Therapeutics will post -1.49 EPS for the current year.

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.